Jpmorgan Chase & CO Bei Gene, Ltd. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 9,780 shares of BGNE stock, worth $1.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,780

Previous 12,488 21.68%

Holding current value

$1.9 Million

Previous $1.78 Million 23.25%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$143.93 - $224.51 $389,762 - $607,973	-2,708 Reduced 21.68%	9,780 $2.2 Million
Q2 2024 Aug 12, 2024	SELL	$129.52 - $174.32 $312,013 - $419,936	-2,409 Reduced 16.17%	12,488 $1.78 Million
Q1 2024 May 10, 2024	BUY	$141.8 - $181.47 $470,776 - $602,480	3,320 Added 28.68%	14,897 $2.33 Million
Q4 2023 Feb 12, 2024	SELL	$158.67 - $201.58 $92,028 - $116,916	-580 Reduced 4.77%	11,577 $2.09 Million
Q3 2023 Nov 14, 2023	SELL	$179.87 - $225.13 $565,691 - $708,033	-3,145 Reduced 20.55%	12,157 $2.19 Million
Q2 2023 Aug 11, 2023	SELL	$178.3 - $266.78 $1.49 Million - $2.22 Million	-8,335 Reduced 35.26%	15,302 $2.73 Million
Q1 2023 May 11, 2023	BUY	$215.53 - $274.5 $540,980 - $688,995	2,510 Added 11.88%	23,637 $5.09 Million
Q4 2022 Feb 13, 2023	SELL	$125.51 - $229.3 $5.64 Million - $10.3 Million	-44,950 Reduced 68.03%	21,127 $4.65 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $4.82 Million - $7.39 Million	-36,542 Reduced 35.61%	66,077 $8.91 Million
Q2 2022 Aug 11, 2022	SELL	$121.11 - $216.05 $1.67 Million - $2.98 Million	-13,779 Reduced 11.84%	102,619 $16.6 Million
Q1 2022 May 11, 2022	SELL	$146.52 - $269.56 $2.83 Million - $5.21 Million	-19,336 Reduced 14.25%	116,398 $22 Million
Q4 2021 Feb 10, 2022	SELL	$248.56 - $389.34 $9.14 Million - $14.3 Million	-36,762 Reduced 21.31%	135,734 $36.8 Million
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $43.1 Million - $69.5 Million	172,496 New	172,496 $62.6 Million

Others Institutions Holding BGNE

# of Institutions

249

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.1B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Bei Gene, Ltd. Transaction History